The Cost-Effectiveness of Avatrombopag Versus Eltrombopag and Romiplostim in the Treatment of Patients with Immune Thrombocytopenia in the UK

Background: Thrombopoietin receptor agonists—romiplostim, eltrombopag and avatrombopag—are commonly used as second-line treatments for immune thrombocytopenia (ITP). Methods: A Markov model was developed to estimate the cost effectiveness of the three TPO-RAs in adults with insufficient response to...

Celý popis

Podrobná bibliografie

Hlavní autoři:	Nichola Cooper, Sebastian Guterres, Michał Pochopień, Koo Wilson, Sam James, Mondher Toumi, Anna Tytuła, Carly Rich, Daniel Eriksson
Médium:	Artigo
Jazyk:	Inglês
Vydáno:	MDPI AG 2025-03-01
Edice:	Journal of Market Access & Health Policy
Témata:	avatrombopag cost-effectiveness eltrombopag immune thrombocytopenia incremental cost-effectiveness ratio romiplostim
On-line přístup:	https://www.mdpi.com/2001-6689/13/2/11
Tagy:	Přidat tag Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!